Antin Infrastructure Partners Announces a Voluntary Cash Tender Offer for 100% of Opdenergy
Cash tender offer at €5.85 per share with intention to delist Opdenergy shares The price…
News
Vivid Fire Kitchen Heats Up Vivid Sydney 2023 With A Sizzling Local Line-Up
SINGAPORE June 12, 2023 – (ACN Newswire) – The Vivid Food program presents a stellar…
Dynasty Launches New NIANHUA Series in 2023 to Meet Needs of Different Consumer Groups
HONG KONG, Jun 12, 2023 – (ACN Newswire) – Dynasty Fine Wines Group Limited (“Dynasty”…
TapestryX Protocol Rated by the Government Blockchain Association (GBA)
Washington, D.C., Jun 12, 2023 – (ACN Newswire) – TapestryX (https://tapestryx.com), a layer one blockchain…
Andreessen Horowitz (“a16z”) Announces its First International Expansion to the United Kingdom
The company’s crypto practice, which manages $7.6 billion (£6.05 billion) of committed capital, will establish…
Tech Alert: BrainChip Examines New Approach to Optimizing Time-series Data
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–A new white paper by BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF,…
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for…
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg…
Reyna Law Firm Enters American Academy of Attorneys’ 500 Million Dollar Club
Reyna Law Firm announced its recent induction in the American Academy of Attorneys’ 500 Million…
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in…
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment…
Aptose Presents Highlights from Clinical Update
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across…
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with…
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
– Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition…
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month…
WiseSight and T2 Systems, a Verra Mobility Company Have Created an Integration to Provide AI-Based Automated Enforcement for Surface Lots and Street Parking
Parking technology leaders are collaborating to provide automated enforcement using advanced AI technologies INDIANAPOLIS–(BUSINESS WIRE)–#AI–WISESIGHT…
Bellabeat Introduces Meditation Rooms for Corporate Wellness Plans to Boost Employee Well-Being
San Francisco, California–(Newsfile Corp. – June 9, 2023) – Bellabeat, a trailblazing femtech company, has…
One Page Case Studies Launches Local SEO Mastermind for Business Owners
Wilton, Connecticut–(Newsfile Corp. – June 9, 2023) – In an era where online visibility is…
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global…
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR…